In vivo simulation of human pharmacokinetics in the rabbit

被引:23
作者
Bugnon, D
Potel, G
Caillon, J
Baron, D
Drugeon, HB
Feigel, P
Kergueris, MF
机构
[1] Fac Med Nantes, Lab Antibiol Clin & Expt, F-44035 Nantes, France
[2] Ctr Hosp Dept Les Oudairies, Serv Reanimat, F-85025 La Roche sur Yon, France
[3] CHU Nantes, Pharmacol Lab, F-44000 Nantes, France
关键词
D O I
10.1006/bulm.1997.0013
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
The evaluation of drugs in vivo is often based on experimental models using small animals such as mice, rats and rabbits. However, these models could be improved to correspond more closely to the human situation if the pharmacokinetics of the drugs tested in animals were similar to that observed in humans. The use of a computer-controlled pump allowing an adequate flow of tobramycin and amikacin to be infused into rabbits enabled us to simulate the human pharmacokinetics of these antibiotics in vivo in this study. The function defining the rate of infusion required to perform the simulation of an intravenous bolus was first determined generally and symbolically for linear pharmacokinetic models independently from the number of compartments involved. The practical simulation of a decreasing monoexponential serum profile with a half-life of 2 h (one-compartment model for the human pharmacokinetics of aminoglycosides) was then studied for tobramycin and amikacin on the basis of a two-compartment model in the animal. The kinetics obtained had an apparent elimination half-life of 1.97 and 1.86 h, respectively. Linearity of the semilogarithmic regressions of the profiles obtained was quite sound. Finally, an a posteriori analysis of the pharmacokinetic model and its parameters is proposed on the basis of the results obtained after simulation. (C) 1998 Society for Mathematical Biology.
引用
收藏
页码:545 / 567
页数:23
相关论文
共 14 条
[1]  
BARD Y, 1974, NONLINEAR PARAMETER, P170
[2]   INTERSPECIES SCALING, ALLOMETRY, PHYSIOLOGICAL TIME, AND THE GROUND PLAN OF PHARMACOKINETICS [J].
BOXENBAUM, H .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1982, 10 (02) :201-225
[3]   In vivo antibacterial effects of simulated human serum profiles of once-daily versus thrice-daily dosing of amikacin in a Serratia marcescens endocarditis experimental model [J].
Bugnon, D ;
Potel, G ;
Xiong, YQ ;
Caillon, J ;
Kergueris, MF ;
LeConte, P ;
Baron, D ;
Drugeon, H .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (05) :1164-1169
[4]   PHARMACODYNAMICS OF AMIKACIN INVITRO AND IN MOUSE THIGH AND LUNG INFECTIONS [J].
CRAIG, WA ;
REDINGTON, J ;
EBERT, SC .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1991, 27 :29-40
[5]  
FANTIN B, 1990, J ANTIMICROB CHEMOTH, V27, P829
[6]   SIMULATION OF AMOXICILLIN PHARMACOKINETICS IN HUMANS FOR THE PREVENTION OF STREPTOCOCCAL ENDOCARDITIS IN RATS [J].
FLUCKIGER, U ;
MOREILLON, P ;
BLASER, J ;
BICKLE, M ;
GLAUSER, MP ;
FRANCIOLI, P .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (12) :2846-2849
[7]   ANTIBIOTIC-THERAPY OF INFECTIONS DUE TO PSEUDOMONAS-AERUGINOSA IN NORMAL AND GRANULOCYTOPENIC MICE - COMPARISON OF MURINE AND HUMAN PHARMACOKINETICS [J].
GERBER, AU ;
BRUGGER, HP ;
FELLER, C ;
STRITZKO, T ;
STALDER, B .
JOURNAL OF INFECTIOUS DISEASES, 1986, 153 (01) :90-97
[8]  
JOLLEY ME, 1981, CLIN CHEM, V27, P1190
[9]   COMPARATIVE ANTIBIOTIC DOSE-EFFECT RELATIONS AT SEVERAL DOSING INTERVALS IN MURINE PNEUMONITIS AND THIGH-INFECTION MODELS [J].
LEGGETT, JE ;
FANTIN, B ;
EBERT, S ;
TOTSUKA, K ;
VOGELMAN, B ;
CALAME, W ;
MATTIE, H ;
CRAIG, WA .
JOURNAL OF INFECTIOUS DISEASES, 1989, 159 (02) :281-292
[10]   NONLINEAR MIXED EFFECTS MODELS FOR REPEATED MEASURES DATA [J].
LINDSTROM, MJ ;
BATES, DM .
BIOMETRICS, 1990, 46 (03) :673-687